TrialOncotarget2017

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.

Rudolf A Werner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.